

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

COMPLETION ON VERY SUBSTANTIAL ACQUISITION

Reference is made to the circular of the Company dated 12 February 2018 (the “**Circular**”) in relation to the Proposed Acquisition. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The Board is pleased to announce that all the conditions precedent to the Proposed Acquisition as set out in the Equity Interest Transfer Agreement have been fulfilled and completed on 31 May 2018. Upon Completion, the Target Company has become a non-wholly-owned subsidiary of the Company and the financial results of the Target Group will be consolidated into the Group’s financial statements.

The Board of

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 4 June 2018

As at the date of this announcement, the board of directors of the Company comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong and Mr. Wu Changhai as executive directors, and Mr. Chu Xiaoping, Mr. Jiang Wenqi, Mr. Wong Hin Wing and Ms. Wang Weihong as independent non-executive directors.